Loading
ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven.
ROR1 is an oncofetal receptor tyrosine kinase-like protein, a Wnt5a pseudo-kinase receptor that drives survival signalling in CLL and mantle cell lymphoma and is largely absent from normal adult tissue. Surface expression is seen in over 90% of CLL, 30-50% of DLBCL, and 40-60% of TNBC by IHC, with NSCLC expression also reported. Zilovertamab vedotin (MK-2140), an ADC, is in phase 3 in DLBCL, and the TNBC and NSCLC expression supports solid-tumour programmes. Because the receptor is a pseudo-kinase, it is used as a delivery address rather than a signalling target, and whether expression level predicts ADC benefit remains to be shown. The simple version is an embryonic receptor that many cancers re-express, giving ADCs a target largely missing from healthy cells.
In plain words · ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven.
ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven.
Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
1 product aims at ROR1: antibody-drug conjugates. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Zilovertamab vedotin) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA ROR1: RNA tissue enhanced (parathyroid gland 23 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas ROR1 tissue; Human Protein Atlas ROR1 pathology; Open Targets ENSG00000185483 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Masiakowski et al, J. Biol. Chem, 1992, "A novel family of cell surface receptors with tyrosine kinase-like domain". Source.
Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.
RNA: tissue enhanced (parathyroid gland 23 nTPM), detected in many normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Chronic lymphocytic leukaemia | >90% | Surface expression | Wikipedia | |
| Triple-negative breast cancer | 40-60% | IHC, any expression | Wikipedia | |
| Diffuse large B-cell lymphoma | 30-50% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Zilovertamab vedotin is a ROR1-directed ADC in phase 3 for large B-cell lymphoma.
Query for this target: (TITLE:"ROR1" OR ABSTRACT:"ROR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ROR1, not a curated reading list.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC) and the tag adc-target.
Shares Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma and the tag adc-target.
Shares Antibody-drug conjugate (ADC) and the tag adc-target.